TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Axillary Plexus Block - Dose Reduction of Prilocaine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* elective surgery on the distal forearm or the hand~* adult outpatients, age 18-75 years old~* ASA-risk groups I-II (American Society of Anesthesiologists)~* Body Mass Index 17-35~* informed consent~Exclusion Criteria:~* severe coagulopathy~* local or systemic inflammatory response~* ASA-risk groups ≥ Grad III~* severe anemia~* heart failure~* manifest shock~* other drugs with influence on methaemoglobinemia (nitrates, sulfonamides etc.)~* domestic care after surgery not ensured~* drug allergy : local anesthetics~* severe polyneuropathy~* pregnancy, lactation period~* participation in other studies~* non-cooperative patients~* addiction to drugs or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- group A : 40ml Prilocaine 1% (Type: ACTIVE_COMPARATOR): 40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block
- group B : 30ml Prilocaine 1% (Type: ACTIVE_COMPARATOR): 40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
- group C : 20ml Prilocaine 1% (Type: ACTIVE_COMPARATOR): 40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. History of symptomatic gout defined as:~   1. ≥ 3 gout flares within 18 months of Screening or~  2. Presence of ≥ 1 tophus or~  3. Current diagnosis of gouty arthritis~2. At the Screening Visit: male age 21 - 80 years, inclusive, or female of non-childbearing potential age 21-80 years, inclusive, where non-childbearing potential is defined as:~   1. \> 6 weeks after hysterectomy with or without surgical bilateral salpingooperhectony or~  2. Post-menopausal (\> 24 months of natural amenorrhea)~3. Has at the Screening Visit SUA ≥ 7 mg/dL, with chronic refractory gout defined as having failed to normalize SUA and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the medically appropriate dose or for whom these drugs are contraindicated;~4. Willing to provide written informed consent prior to the conduct of any study specific procedures;~5. Understands and is willing and able to comply with study requirements, including the schedule of follow-up visits~Key Exclusion Criteria:~1. Prior exposure to any experimental or marketed uricase (e.g., pegloticase \[Krystexxa®\], pegadricase \[SEL-037\], rasburicase \[Elitek, Fasturtec\]);~2. History of anaphylaxis or severe allergic reactions to medications;~3. History of any allergy to pegylated products~4. Drugs known to interact with Rapamune cannot be used during the trial;~5. Uncontrolled diabetes;~6. Glucose-6-phosphate dehydrogenase (G6PD) deficiency;~7. Uncontrolled hypertension;~8. Participants whose arrhythmia is unstable on current treatment;~9. History of coronary artery disease, including myocardial infarction or unstable angina, within the last 6 months;~10. Congestive heart failure;~11. History of hematological disorders within 1 year or autoimmune disorders, is immunosuppressed or immunocompromised;~12. Has received an inactivated vaccine in the previous 3 months or has received a live virus vaccine in the previous 6 months;~13. Is planning to receive any vaccination or live virus vaccination during the study;

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- SEL-212 (Type: EXPERIMENTAL): Intravenous (IV) infusion of SEL-212 every 28 days for up to 6 infusions
- KRYSTEXXA (Type: ACTIVE_COMPARATOR): IV infusion of KRYSTEXXA® according to the manufacturer's prescribing information every 14 days for up to 12 infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~* Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3~* Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5~* Last fully preserved single neurological level (SNL) from C-4 to C-7~* From 18 through 69 years of age at time of injury~* Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI) scan, with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring~* Informed consent for this protocol and the companion long term follow-up protocol must be provided and documented (i.e., signed informed consent forms) no later than 37 days following injury~* Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days following SCI~Major Exclusion Criteria:~* SCI due to penetrating trauma~* Traumatic anatomical transection or laceration of the spinal cord based on prior surgery or MRI~* Any concomitant injury that interferes with the performance, interpretation or validity of neurological examinations~* Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised~* Significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression~* History of any malignancy (except non-melanoma skin cancers)~* Pregnant or nursing women~* Body mass index (BMI) \> 35 or weight \> 300 lbs.~* Active participation in another experimental procedure/intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- AST-OPC1 (Type: EXPERIMENTAL): Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Urate Elevation in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic PD with at least two of the cardinal signs of PD (resting tremor, bradykinesia, rigidity)~* Currently not taking or needing any treatment for PD other than an monoamine oxidase-B (MAO-B) inhibitor~* Age 30 or older at the time of PD diagnosis~* Diagnosis of PD made within past 3 years~* Serum urate ≤ 5.8 mg/dL at initial screening~Exclusion Criteria:~* History of kidney stones, gout, stroke, or heart attack~* History of renal disease or certain cardiovascular problems within the past year~* Acidic urine (pH ≤ 5.0), uric acid, or urate crystalluria at screening~* Use of certain medications including co-enzyme Q, creatine, more than 50 IU of vitamin E daily, and more than 300 mg of vitamin C daily. (A standard daily multivitamin is permitted.)~* Use of anti-PD and other medications targeting central nervous system dopamine transmission~* Known unstable medical or psychiatric condition that may compromise participation in the study~* Women who are pregnant or lactating

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [A:] (Type: PLACEBO_COMPARATOR): Placebo to produce no urate elevation
- [B:] (Type: EXPERIMENTAL): Inosine to produce a mild urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
- [C.] (Type: EXPERIMENTAL): Inosine to produce a moderate urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age- 18-75 years~2. Patients in paroxysmal, persistent or long-standing persistent (LSP) AF~3. patients with CHADS2 score ≥ 1~4. AF patients with INR in the range of 2.0-3.0 in the last 3-4 weeks prior to ablation~Exclusion Criteria:~1. Patients with known bleeding disorders or inherited thrombophilic disorder~2. Patients with oral contraceptives or estrogen replacement therapy~3. Patients with prosthetic heart valves~4. Patients unable or willing to give informed consent~5. Contraindications for Coumadin therapy~6. Patients with CHADS2 score zero~7. Contraindication to undergoing an MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study Arm (Type: ACTIVE_COMPARATOR): Patients receive continuous Coumadin therapy throughout the study.
- Control Arm (Type: ACTIVE_COMPARATOR): Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thoracic Paravertebral Block in Pain Management After Renal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age 18-75~* Scheduled for elective open nephrectomy or NSS~* Gave written consent~* BMI 19-30~* ASA status I-III~Exclusion criteria:~* Presence of chronic pain~* Chronic mental conditions (depression)~* Contraindications for PVB~* Chest or spine deformations~* Infection in planned site of PVB~* Allergies for drugs used in the study~* Cancer invading chest wall

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PVB group (Type: EXPERIMENTAL): Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
- GEN group (Type: OTHER): Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between the ages of 18 and 75 years.~* Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months.~* Have a PASI score of 12 or greater AND a Physician Global Assessment score of 3 (moderate) or 4 (severe).~* Have plaque-type psoriasis covering at least 10 % of total body surface area (BSA).~Exclusion Criteria:~* Have non-plaque forms of psoriasis.~* Drug-induced psoriasis.~* Current active infection.~* Infected with Mycobacterium tuberculosis (TB).~* Have any history of malignancies.~* Require treatment with prohibited concomitant medications(s).~* Positive for hepatitis B or C, or human immunodeficiency virus (HIV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06826647 Drug Dose Level 1 (Type: EXPERIMENTAL): Delivered orally for 16 weeks during the Investigational Treatment Period
- PF-06826647 Placebo (Type: EXPERIMENTAL): Delivered orally for 16 weeks during the Investigational Treatment Period
- PF-06826647 Drug Dose Level 2 (Type: EXPERIMENTAL): Delivered orally for 16 weeks during the Investigational Treatment Period
- PF-06826647 Drug Dose Level 3 (Type: EXPERIMENTAL): Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
- PF-06826647 Drug Dose Level 4 (Type: EXPERIMENTAL): Delivered orally for 16 weeks then for 24 weeks in Extension Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. age:18-75 years, male or femal.~2. Histologically confirmed primary Squamous Cell Carcinoma of the Esophagus,Local advanced esophageal cancer diagnosed by pathology and imaging,clinical stage T3-4N0M0, T1-4N+M0,Ⅱ-Ⅳa.~3. Pre-treatment evaluation can not tolerate concurrent radiochemotherapy or rejection of the concurrent use of chemotherapy with radiotherapy.~4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.~5. ECOG 0-1.~6. Adequate organ function.~7. Life expectancy of greater than 6 months.~8. Patient has given written informed consent.~Exclusion Criteria:~1. Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy.~2. Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR- 1210 formulation.~3. Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ);~4. Subjects with any active autoimmune disease or history of autoimmune disease~5. Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;~6. Active infection or an unexplained fever \> 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);~7. Received a live vaccine within 4 weeks of the first dose of study medication.~8. Pregnancy or breast feeding.~9. Decision of unsuitableness by principal investigator or physician-in-charge.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SHR-1210+ Radiotherapy (Type: EXPERIMENTAL): Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed type 2 diabetes patients based on American Diabetes Association criteria (2011) for diagnosis of diabetes~Exclusion Criteria:~* previous intake of oral hypoglycemic agents for treatment of diabetes or other hyperglycemia associated conditions~* intake of glucocorticoids in the past one year~* major illnesses of heart, lung, kidney, and liver.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): patients receiving fixed dose metformin 1000 mg daily
- Pioglitazone (Type: ACTIVE_COMPARATOR): patients receiving fixed dose pioglitazone 30 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms and signs of congestive heart failure~* Recent Imaging Study (\<12 months) showing Left Ventricular Ejection Fraction (LVEF) \>50% and Left Ventricular End Diastolic Volume Index (LVEDVI) \<97ml/m2~* Evidence of abnormal Left Ventricular (LV) relaxation, filling, diastolic distensibility, and diastolic stiffness as shown by one of the following:~  1. Invasive Hemodynamic measurements~     * mean Pulmonary Capillary Wedge pressure (mPCW) \>12~    * Left Ventricular End Diastolic Pressure (LVEDP) \>16 mmHg~ 2. Tissue Doppler Echocardiogram~     * E/E' \>15~    * E/E' 8-15 and one of the following~       * Left Ventricular Hypertrophy (LVH)~      * Atrial Fibrillation~      * Left Atrial Enlargement~      * E/A \<0.5 + Deceleration Time (DT) \>280 (if \>50yrs of age)~ 3. Biomarkers~* Brain Natriuretic Peptide (BNP) \>200pg/mL~Exclusion Criteria:~* Age \<18~* Recent changes (previous 3 months) in HF maintenance medications (beta-blockers, angiotensin converting enzyme \[ACE\] inhibitors, aldosterone antagonists, vasodilators, cardiac glycosides, diuretics)~* Hospitalization for worsening Heart Failure (HF) or acute decompensated HF within the previous 12months~* Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable cardioverter defibrillator (AICD)~* Angina or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing~* Active infection including chronic infection~* Active cancer~* Recent (\<14 days) use of anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs \[NSAIDs\]), Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus), malignancy, or any comorbidity limiting survival or ability to complete the study~* Pregnancy (determined by urine pregnancy test in women of childbearing potential)~* Inability to give informed consent~* Other conditions limiting completion of cardiopulmonary exercise test or completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Treatment with daily subcutaneous injections of Anakinra 100 mg
- Placebo (Type: PLACEBO_COMPARATOR): Treatment with daily subcutaneous injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Less than age of 60 year at the time of pretransplant evaluation.~2. An established clinical diagnosis of systemic lupus erythematosus with one of the following features:~   1. Lupus nephritis-WHO class III or IV (or V when coexistent III or IV) lupus nephritis, failing NIH short course cyclophosphamide therapy (10mg/kg q month for 6 months). Failure will be defined as failure of creatinine to return to normal or pre-exacerbation level.~  2. Vasculitis/Immune complex deposition- causing end organ signs or symptoms e.g. cerebritis, transverse myelitis, pulmonary hemorrhage, cardiac failure, renal failure.~  3. Cytopenias that are immune-mediated and not controlled by conservative measures including danzole, prednisone, and alkylating agents (cyclophosphamide or vincristine); and any one of the following: transfusion dependant anemia with untransfused hemoglobin less than 8 grams/dl, or platelets less than 40,000/ul without transfusions,or granulocytes less than 1000/ul.~  4. Catastrophic Anti-phospholipid Syndrome~4. Ability and willingness to provide informed consent.~Exclusion Criteria:~1. Human immunodeficiency virus (HIV)positive status.~2. History of unstable angina.~3. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemoradiotherapy.~4. Prior history of malignancy except for localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis.~5. Positive serum pregnancy test, inability or unwillingness to pursue effective means of birth control or failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.~6. Psychiatric illness or mental deficiency not due to active lupus cerebritis making compliance with treatment or informed consent impossible.~7. FEV1/FVC\<50% of predicted, DLCO \<50%of predicted.~8. Resting left ventricular ejection fraction(LVEF)\<35% or lupus induced myocarditis.~9. Known hypersensitivity to Escherichia coli.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete